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ABSTRACT 
This is the first study of changes in protein glycosylation due to exposure of human subjects 
to ionizing radiation. Site specific glycosylation patterns of 7 major plasma proteins were 
analyzed; 171 glycoforms were identified; and the abundance of 99 of these was followed in 
the course of cancer radiotherapy in 10 individual patients. It was found that glycosylation of 
plasma proteins does change in response to partial body irradiation (~60 Gy), and the effects 
last during follow-up; the abundance of some glycoforms changed more than twofold. Both 
the degree of changes and their time-evolution showed large inter-individual variability. 
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HIGHLIGHTS: 
 first human study to show that ionizing radiation does change protein glycosylation 
 glycosylation of 7 major plasma proteins in 10 individual cases were followed 
 changes of protein glycosylation in response to radiotherapy last for several weeks 
 
KEYWORDS: head and neck cancer, glycosylation, proteomics, glycosylation pattern, 
radiotherapy 
  
 3 
 
1 Introduction 
Radiation has been always a very important factor influencing living organisms. Radiation 
comes from accidental, intentional or natural sources; we can differentiate environmental, 
industrial, occupational (in wars) radiation, radiological terror and medicinal radiotherapy. 
In radiobiology there is an increasing interest in proteomics nowadays [1-3]. The response for 
radiation was often studied on the genome level. However DNA damage is only part of the 
picture; changes in cellular structure; in protein composition of cells and biological fluids are 
also needed to understand molecular mechanisms and micro-environmental consequences of 
radiation. Furthermore, radiation may induce changes in higher order organisms. Beside 
genetics, proteomics may offer new insights, describing new pathophysiological pathways or 
discovering new biomarker candidates [4-10] to assess the influence of radiation on living, 
multicellular organisms. Note, that especially in multicellular organisms, the long-term 
response of the organism to radiation may even be more important, than radiation damage 
itself. Cell-cell communication; partly mediated by biological fluids like blood, often involves 
glycosylation. Bearing these in mind, in the present paper we focus on evaluating long-term 
glycosylation changes in plasma proteins. 
Diversity of proteins and types of molecular pathways they are involved in are enormously 
expanded due to post-translational modifications. Effects of radiation has already been studied 
in case of phosphorylation [6, 11-13], acetylation [12], ubiquitination [14], carbonylation [15, 
16], nitrosylation [15, 16] and glycosylation [17-20] in different tissues and biofluids and in 
some cases significant alterations were found.  
Glycosylation is one of the most important and most common post-translational modification 
of proteins. Glycosylation has important biological roles: it takes part in transport of proteins, 
immune response, communication between cells and several human plasma glycoproteins 
have been proved to be biomarkers for different diseases [21-24]. From analytical point of 
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view there are two ways (and combination of these) to characterize glycosylation: 1) 
Averaging glycosylation data: before analysis glycans are removed from proteins using 
specific enzymes (e.g.: N-glycans are cleaved with PNGaseF) or acidic hydrolysis, and then 
released glycan mixture is characterized by the number of antennas and sialic acid residues. In 
this case important information about attachment sites of glycans is lost. 2) Site-specific 
glycosylation patterns are carrying more and different biological information: proteins are 
digested using endoproteases (e.g.: trypsin) and resulted glycopeptides are analyzed, therefore 
glycosylation sites and site-specific distribution of glycans can also be determined. [25-28] 
To our knowledge there are only a few studies published about the relationship between 
glycosylation and ionizing radiation. 1) Dorsal skin irradiation of mice was performed at 
different doses (20, 40 and 80 Gy) and serum proteins were analyzed using two dimensional 
differential in-gel electrophoresis. Glycans were analyzed after they were removed from the 
proteins using mass spectrometry. Shifts in the isoelectric point (pI) were observed [17, 29] 
possibly caused by changes in glycosylation, and decrease in biantennary structure, increase 
in multiantennary N-glycans, outer branch fucosylation and sialylation was found [17]. 
However, because averaging glycosylation was studied, there was no information whether 
changes in glycosylation involved all, or only some specific proteins. 2) In another study [20] 
mice were exposed to ionizing radiation (0, 3, 6 and 10 Gy) and plasma glycoproteins were 
analyzed using lectins. Time and dose dependent alterations of glycoproteins containing 
galactose, N-acetylgalactosamine and mannose were found, however there was no significant 
difference in the plasma glycoprotein level. 3) In colon cancer cells, correlation between 
radiation-mediated sialylation of integrin β1 (glycosylated cell surface protein) and increased 
radio-resistance was observed [18, 19]. 
In the current study site-specific glycosylation pattern of plasma proteins was analyzed from 
human samples. Patients suffering from head and neck cancer were treated with radiotherapy 
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(RT). Site-specific glycosylation pattern was determined from samples collected before, 
during and after the treatment. We observed that glycosylation of various proteins changed 
significantly, which may help to better understand the molecular response of the human body 
for radiation. 
 
2 Materials and methods 
2.1 Samples and chemicals 
Ten patients (Caucasians; 50-80-year-old, median 61 years; 7 men) with head and neck 
squamous cell carcinoma (HNSCC) located in larynx (7) or pharynx (3) were enrolled into the 
study. All patients were subjected to intensity-modulated RT (IMRT) using 6-MV photons. 
Total radiation dose delivered to the gross tumor volume (20-148 cm
3
) was in the range of 51-
72 Gy (median 67.2 Gy); overall treatment time was 22-50 days (median 39 days) with dose 
fractions 1.8-3 Gy. Three consecutive blood samples (5 mL each) were collected from each 
patient: pre-treatment sample A, post-treatment sample B collected in the last day of the 
treatment (i.e. after receiving total dose) and post-treatment sample C collected 1-1.5 month 
after the end of RT. Plasma specimen was isolated from EDTA-treated blood after 
centrifugation at 2,000g for 15 minutes, and then stored at -80 
o
C before analysis. The study 
was approved by the appropriate Ethics Committee and all participants provided informed 
consent indicating their conscious and voluntary participation. 
1,4-dithio-L,D-threitol (DTT) and 2-iodoacetamide (IAA) were obtained from Fluka Chemie 
GmbH (Sigma-Aldrich
®
, Zwijndrecht, Netherlands). RapiGest SF (lyophilized sodium-3-[(2-
methyl-2-undecyl-1,3-dioxolan-4-yl)-methoxyl]-1-propane-sulfonate) was purchased from 
Waters (Milford, MA, USA). Mass spectrometry grade trypsin was purchased from Promega 
Corporation (Madison, WI, USA). 
All other reagents were purchased from Sigma-Aldrich
®
 (St. Louis, MO, USA). 
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2.2 Immunoaffinity depletion of plasma samples 
To reduce sample complexity, two high abundance proteins: albumin and IgG were removed 
from human plasma with Agilent Multiple Affinity Removal Spin Cartridge HSA/IgG 
(Agilent Technologies, Santa Clara, CA, USA). 
30 µL plasma sample was loaded onto the cartridge and manufacturer’s standard protocol was 
followed. At the end K2HPO4 and citric acid were added to the diluted samples to prevent 
aggregation (30-30 mM concentration in the samples), and samples were concentrated with 10 
kDa centrifuge filters. After filtration, volume of the depleted plasma sample was 25 µL. 
 
2.3 Fractionation of depleted plasma samples 
Fractionation of depleted plasma samples was performed using Acquity UPLC
® 
System 
(Waters, Milford, MA, USA). 
Poros R2 HPLC column (Poly(Styrene-Divinylbenzene, 10 μm, 2.1 × 100 mm, Applied 
Biosystems, Foster City, CA, USA) was used, and depleted plasma samples were injected in 
15 μL volume. The column temperature was 65 °C, the flow rate was 1 mL/min. The gradient 
was the following: starting with 20% B for 0.7 min, then a 15 min long gradient from 20% to 
70% solvent B, increasing to 95% solvent B in 0.1 min, washing for 1.5 min, returning to 
20% B in 0.1 min and equilibration for 6 min. Solvent A was water containing 0.07 v/v% 
trifluoroacetic acid and solvent B was acetonitrile containing 0.07% v/v trifluoroacetic acid. 
500 μL fractions were collected manually from 4.5 to 5.5 min (two half minute fractions). To 
neutralize TFA and to prevent aggregation 1.3 μL NH3 solution (25 w/w%) and 1.8 μL 
K2HPO4 solution (500 mM) were added to the fractions, and fractions were concentrated to 30 
μL with SpeedVac (miVac Duo Concentrator, Genevac Ltd., Ipswich, Suffolk, UK). 
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Details of this fractionation method and it’s benefits during the analysis of glycoproteins was 
described before [30]. 
 
2.4 In-solution digestion 
Concentrated fractions were digested as the following: after adding 5 μL NH4HCO3 solution 
(200 mM) proteins were unfolded and reduced using 3 μL RapiGest SF solution (0.5 w/v%) 
and 2 μL DTT solution (100 mM) for 30 min at 60 °C. Proteins were alkylated using 4 μL 
NH4HCO3 solution (200 mM) and 2 μL IAA solution (200 mM) for 30 min at room 
temperature in dark. Digestion was performed by adding 1.5 μL trypsin solution (40 μM) for 
180 min at 37 °C. Digestion was stopped by adding 1.5 μL formic acid, followed by 30 min 
incubation at 37 °C. Samples were centrifuged at 13500 rpm (corresponding to 17000 g) for 
10 min. 
 
2.5 nanoLC-MS(/MS) analysis 
Digested fractions were analyzed using nanoAcquity UPLC (Waters, Milford, MA, USA) 
coupled to a high resolution QTOF Premier mass spectrometer (Waters, Milford, MA, USA). 
The chromatographic conditions were the following: Symmetry C18 trap column (180 µm i.d. 
× 20 mm, Waters Milford, MA, USA) and reversed-phase analytical column (C18, 1.7 µm 
BEH particles, 75 µm i.d. × 200 mm, Waters, Milford, MA, USA) were used. Column 
temperature was 55 °C. Using 250 nL/min flow rate the gradient started from 3% to 8% B in 
4 min, followed by a 65 min long gradient going to 40% solvent B. Washing was performed 
using 450 nL/min flow rate and a 2 min long gradient from 40 to 75% solvent B, keeping here 
for 18 min. Finally, after returning to 3% B in 2 min, equilibration was done for 18 min. 
Solvent A was water containing 0.1 v/v% formic acid and solvent B was acetonitrile 
containing 0.1 v/v% formic acid. 
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Protein composition of the digested fractions was determined with tandem mass spectrometry 
using data dependent analysis of the resulted peptides. Conditions were the following: 
Electrospray ionization mode was used, capillary voltage was 2.3 kV, nanoflow 1 bar, source 
temperature 90 °C, cone voltage 35 V. Collision gas was argon, at 4.05 × 10-3 mbar. Collision 
energy was varied in the 7-70 eV range. The parent ion was selected in the 400–1800 m/z 
range, MS/MS spectra were acquired in the 50-2000 m/z range.  
Glycosylation sites and major site-specific glycoforms were identified also with tandem mass 
spectrometry. Most of the parameters were the same as described above, however the parent 
ion was selected in the 780-2000 m/z range and MS/MS spectra were acquired in the 150-
3000 m/z range. Collision energy was varied in the 5-55 eV range. Minor glycoforms and 
relative quantitation were measured with single stage mass spectrometry in extended dynamic 
range mode. Scans were acquired in the 500-2000 m/z range. 
Site-specific glycosylation pattern of the proteins was analyzed by the method described 
earlier [31]. 
 
2.6 Data evaluation 
Protein content of the fractions was identified from MS/MS measurements using ProteinLynx 
Global Server v.2.3 (Waters, Milford, MA, USA) and searched against v.2011_10 of 
SwissProt sequence database with human taxonomy using Mascot Server v.2.2 (Matrix 
Science, London, UK). One missed cleavage was allowed, carbamidomethyl cysteine was set 
as fixed modification. 
MS/MS spectra corresponding to major glycopeptides were automatically evaluated by our 
computer software GlycoMiner v.1.13 Beta [32]. Minor glycopeptide identification and 
relative glycopeptide quantitation were performed from MS measurements using the in-house 
developed computer software GlycoPattern v.2.0 [31]. 
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3 Results and discussion 
The effect of exposure to ionizing radiation on plasma proteins glycosylation was studied for 
first time in case of human samples. Site-specific glycosylation patterns of 7 abundant plasma 
proteins were determined in the case of 10 patients. For each patient samples were collected 
before and after exposure. Pre-treatment sample A was considered as a reference for each 
individual person; sample B represents the change induced in glycosylation due to irradiation; 
while sample C allowed addressing potential long-term effects of the treatment (1-1.5 
months). Seven abundant plasma proteins were selected for analysis: Alpha-1-acid 
glycoprotein (A1AG1_HUMAN, A1AG2_HUMAN, two genetic variants), alpha-2-HS-
glycoprotein (fetuin, FETUA_HUMAN), beta-2-glycoprotein 1 (apolipoprotein H, 
APOH_HUMAN), complement factor H (CFAH_HUMAN), haptoglobin (HPT_HUMAN), 
kininogen-1 (KNG1_HUMAN), and serotransferrin (TRFE_HUMAN). Some of these 
glycoproteins contain various glycosylation sites, which were always treated individually. 
Presence and intensity of complex glycan structures (different glycoforms) on N-
glycopeptides were determined and confirmed by MS/MS measurements of the respective 
glycopeptides. Relative abundance of the various components was based on the 
chromatographic peak area of the respective MS signals. Subsequently these were normalized 
to the sum of the abundance of all glycoforms identified in the given chromatographic run. 
In the course of MS/MS studies we have identified altogether 171 glycoforms characterizing 
the 7 selected proteins. Among these we have selected the 99 glycoforms for a quantitative 
study (those above the limit of quantification). The list of these components, and their relative 
abundances in the “reference” pre-treatment sample A, averaged over the 10 patient samples, 
are shown in Table A. Glycoform abundances vary between the various individuals – the 
average relative standard deviation (biological variability considering the 10 most intense 
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peaks) is 29%. Reproducibility of individual glycoform abundances (variability of sample 
preparation and instrumental analysis) is on average 17%, from which reproducibility of 
instrumental analysis is 8%, using 3-3 replicates. In order to illustrate results and to study the 
influence of radiotherapy on protein glycosylation, first results for one individual will be 
discussed. Subsequently we shall look at glycosylation in other individuals to see, how these 
could be generalized.  
Fig. A shows the glycosylation pattern (relative abundance of various glycoforms) of two 
proteins (alpha-2-HS-glycoprotein and serotransferrin) in the case of a given individual. Dark 
blue indicates abundances before irradiation (sample A); blue that in the course of 
radiotherapy (sample B); while light blue columns that one month after radiotherapy (sample 
C). The three glycosylation patterns are different, showing that radiotherapy does influence 
glycosylation patterns of various proteins. For example Fig. A shows that the relative 
abundance of the biantennary disialylated (BiS2) glycoform at glycosylation site 1 (
432
N) of 
serotransferrin was 16% before radiotherapy in the studied individual. This relative 
abundance decreased to 11% (by 31%) during radiotherapy. One month after finishing 
radiotherapy abundance of this glycoform increased (to 13%), but did not yet reach its 
original abundance. Fig. A illustrates that glycosylation in case “C” is between that of “A” 
and “B”, the same was observed in various other cases as well. This suggests, that after 
irradiation is finished, the glycosylation pattern starts to return to “normal” (i.e. to that before 
irradiation); but one month time is not sufficient for this. Other glycoproteins and other 
persons show analogous changes, although the results quantitatively may be different.  
Changes in the glycosylation pattern due to radiotherapy are shown in a more quantitative 
manner in Fig. B. Here we depict changes in the abundance of various glycoforms (i.e. those 
listed in Table A) in the course of radiotherapy. In the horizontal axis the change in glycoform 
abundance during radiotherapy is shown (that compared to its value before radiotherapy 
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started, i.e. abundance measured in sample B compared to that in sample A). This shows the 
magnitude of change in the various glycoform abundances due to radiotherapy; measured 
when a large amount of radiation dose was already absorbed by the individual. The vertical 
axis shows the glycoform abundance one month after radiotherapy finished compared to the 
abundance before radiotherapy (abundance measured in sample C compared to that in sample 
A).  The figure shows that some glycoforms increased 5-fold, some others decreased 5-fold; 
most showed smaller changes. In the present pilot study, the limited number of patient 
samples preclude a general conclusion, which proteins and which glycoforms are most 
influenced by radiotherapy. This should be established in a subsequent, full scale clinical 
study.  
Fig. B shows that there is a good linear relationship (R
2
=0.8292) between B/A and C/A 
values. Linear correlation between C/A and B/A means, that the change in glycoform 
intensity (compared to the respective value before radiotherapy) during and ca. 1 month after 
radiotherapy are correlated. If the slope is unity, this indicates that radiotherapy induces a 
certain change; and this change becomes fixed (will not change even one month after 
treatment). If the slope is zero, this indicates that the change in glycosylation goes back to the 
“original” value (that before radiotherapy) as soon as radiotherapy is finished. The slope is 
close to, but less than unity (0.87). This suggest that changes in glycosylation induced by 
radiotherapy last for a long time. After radiotherapy is finished, protein glycosylation starts to 
return to the “normal” value (i.e. to that measured before irradiation). The value of the slope 
suggests, that ca. 87% of radiation-induced changes in glycosylation are still present one 
month after irradiation was finished. This implies that the effect of radiotherapy on plasma 
protein glycosylation is likely to last for several months.  
The results described above are qualitatively similar to all other persons studied. Some 
glycoforms increase, some others decrease due to radiotherapy. After irradiation, 
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glycosylation slowly starts to return to “normal”. One month after irradiation is finished, the 
results are somewhere in between that before and during irradiation. One typical example for 
change in glycosylation can be detected in the case of complement factor H (CFAH), a 
protein responsible for activation of the alternate pathway of the complement system. 
Glycosylation of CFAH shows increased fucosylation on all of its glycosylation sites, but the 
rates of change are very different for the different sites. The fucosylation change for CFAH 
glycosylation sites was also observed in liver diseases [33]. 
Glycosylation changes are illustrated in Fig. C, which shows glycoform abundances for all 10 
individuals studied. To account for differences between individuals, glycoform abundances 
during and after radiotherapy were compared to the value measured before radiotherapy for 
each individual. Blue squares (mostly overlapping and thus forming a wide line) indicate the 
abundance of all studied glycoforms during radiotherapy, compared to that before the start of 
radiotherapy (B/A). These data (altogether nearly 800 abundance ratios) are sorted according 
to their value. The orange open circles in the figure show the corresponding C/A ratios (i.e. 
one month after radiotherapy, compared to that before). When the value of the blue squares is 
over unity (i.e. a certain glycoform shows increased abundance due to radiotherapy), there is a 
high (~ 77%) probability, that the corresponding yellow circle will also be over unity (i.e. the 
glycoform will have increased abundance even one month after radiotherapy was finished). In 
an analogous manner, when the value of the blue squares is less than unity (i.e. radiotherapy 
depletes abundance of a certain glycoform) the orange circle will also be below unity (i.e. will 
remain depleted for a long time). Note, mainly due to random errors, smaller than ~20% 
changes in glycoform abundance could not be evaluated.  
During the glycosylation analysis of irradiated mice serum samples Chaze et al. [17] observed 
the decrease of biantennary structures; and increase of tri- tetra- and pentaantennary N-
glycans, outer branch fucosylation and sialylation. No difference was measured in the 
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expression of genes involved in the synthesis of biantennary N-glycans, however genes 
implicated in the multiantennary N-glycan synthesis were found to be overexpressed. 
However, Chaze et al. analyzed only removed glycans, therefore information about the 
proteins containing these glycan structures was lost. Only site-specific glycosylation analysis 
could give the answer, whether the changes in the intensity of different glycan structures were 
caused by changes in the abundance of modified proteins with these particular structures or by 
increases in particular structures linked to different proteins. Note that both in human and in 
mouse studies a small, few cm
2
 surface was irradiated. However, in mouse this represents ca. 
10% of body volume (so irradiation can be considered systemic); while in humans it is only 
ca. 0.01% body volume; so it is clearly localized.  
Analyzing site-specific data of all human individuals we observed that intensity of 44% of 
glycoforms increased and 56% decreased. Correlation between the direction of intensity 
changes (increasing or decreasing) and the following parameters was studied: a) different 
proteins, b) different complex sugar types on glycoforms (number of antennas, number of 
sialic acids and fucoses) and c) different human individuals, but in contrast to the mice 
samples no correlation was found. This means that the study of site-specific glycosylation 
pattern is essential in case of human samples for each glycoform of any protein and 
individual, because from the cleaved mixture of sugars we couldn’t recognize the effect of 
irradiation on glycosylation. 
 
4 Conclusions 
This is the first human study to show that local body irradiation during cancer radiotherapy 
does change glycosylation of plasma proteins. As glycosylation is involved in various 
immunological processes and cell-cell communications, this may have impact on efficacy and 
side effects of radiotherapy. We have studied glycosylation of 7 major plasma proteins in 10 
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individual cases. In the course of the study we have followed changes in the abundance of 99 
glycoforms during radiotherapy. All studied proteins showed glycosylation changes– in most 
cases 20-30% change in glycoform abundances were observed due to irradiation, although in 
many cases larger than twofold changes were also found. Note, that these are plasma proteins 
– i.e. reflect changes in the organism, and not directly related to tissue damage (which occurs 
in a small body volume only). Compared to other post-translational modification studies these 
changes can be considered highly significant: in cells after treatment with 10 Gy ionizing 
radiation only about 1% of quantified phosphoproteins was found to be upregulated more than 
2-fold, and about 3.5% were upregulated over 1.5-fold [12]. The results show that 
radiotherapy changes protein glycosylation for a long period: One month after finishing 
radiotherapy, the glycosylation profile only starts to return to “normal” (i.e. that before 
radiotherapy commenced), which indicated long-term effects of radiation. The results suggest 
that therapeutic radiation induces changes in the whole human body, and these changes last 
for a long period (several weeks or months). The present experiments showed large inter-
individual differences. The number of individuals in the present study was insufficient to 
determine, if glycosylation changes may be used to assess the efficiency of radiotherapy; or 
the healing capacity of the individual.  
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7 Appendices 
Table A: List of selected glycoforms for quantitative study and their relative 
abundances. 
List of selected glycoforms for quantitative study and their relative abundances in sample “A” 
averaged over the 10 patients’ samples. 
Uniprot entry 
name 
Glycopeptide sequence 
sugar type 
Relative 
abundances 
m/z 
charge state: 3+ 
APOH_HUMAN LGNWSAMPSCK_BiS0F0 0,0016 958.3873 
APOH_HUMAN LGNWSAMPSCK_BiS1F0 0,0568 1055.4191 
APOH_HUMAN LGNWSAMPSCK_BiS1F1 0,0055 1104.1050 
APOH_HUMAN LGNWSAMPSCK_BiS2F0 0,1797 1152.4509 
APOH_HUMAN LGNWSAMPSCK_BiS2F1 0,0085 1201.1368 
APOH_HUMAN LGNWSAMPSCK_TriS1F0 0,0022 1177.1298 
APOH_HUMAN LGNWSAMPSCK_TriS2F0 0,0058 1274.1616 
APOH_HUMAN LGNWSAMPSCK_TriS2F1 0,0034 1322.8476 
APOH_HUMAN LGNWSAMPSCK_TriS3F0 0,0088 1371.1934 
APOH_HUMAN LGNWSAMPSCK_TriS3F1 0,0091 1419.8794 
APOH_HUMAN VYKPSAGNNSLYR_BiS1F0 0,0070 1128.1486 
APOH_HUMAN VYKPSAGNNSLYR_BiS1F1 0,0012 1176.8346 
APOH_HUMAN VYKPSAGNNSLYR_BiS2F0 0,1638 1225.1804 
APOH_HUMAN VYKPSAGNNSLYR_BiS2F1 0,0518 1273.8664 
APOH_HUMAN VYKPSAGNNSLYR_TriS2F0 0,0034 1346.8912 
APOH_HUMAN VYKPSAGNNSLYR_TriS3F0 0,0234 1443.9230 
APOH_HUMAN VYKPSAGNNSLYR_TriS3F1 0,0212 1492.6089 
CFAH_HUMAN ISEENETTCYMGK_BiS1F0 0,0121 1159.1142 
CFAH_HUMAN ISEENETTCYMGK_BiS2F0 0,0740 1256.1460 
CFAH_HUMAN ISEENETTCYMGK_BiS2F1 0,0021 1304.8319 
CFAH_HUMAN ISEENETTCYMGK_TriS2F0 0,0028 1377.8567 
CFAH_HUMAN ISEENETTCYMGK_TriS3F0 0,0040 1474.8885 
CFAH_HUMAN MDGASNVTCINSR_BiS1F0 0,0139 1113.4391 
CFAH_HUMAN MDGASNVTCINSR_BiS2F0 0,0944 1210.4709 
CFAH_HUMAN MDGASNVTCINSR_BiS2F1 0,0017 1259.1569 
CFAH_HUMAN IPCSQPPQIEHGTINSSR_BiS1F0 0,0187 1312.2262 
CFAH_HUMAN IPCSQPPQIEHGTINSSR_BiS1F1 0,0035 1360.9121 
CFAH_HUMAN IPCSQPPQIEHGTINSSR_BiS2F0 0,1070 1409.2580 
CFAH_HUMAN IPCSQPPQIEHGTINSSR_BiS2F1 0,0071 1457.9439 
CFAH_HUMAN IPCSQPPQIEHGTINSSR_TriS3F0 0,0009 1628.0005 
KNG1_HUMAN LNAENNATFYFK_BiS2F0 0,0136 1212.8258 
KNG1_HUMAN LNAENNATFYFK_BiS2F1 0,0030 1261.5117 
KNG1_HUMAN LNAENNATFYFK_TriS2F0 0,0012 1334.5365 
KNG1_HUMAN LNAENNATFYFK_TriS2F1 0,0022 1383.2225 
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KNG1_HUMAN LNAENNATFYFK_TriS3F0 0,0051 1431.5683 
KNG1_HUMAN LNAENNATFYFK_TriS3F1 0,0113 1480.2543 
KNG1_HUMAN ITYSIVQTNCSK_BiS1F0 0,0018 1109.7986 
KNG1_HUMAN ITYSIVQTNCSK_BiS2F0 0,0208 1206.8304 
KNG1_HUMAN ITYSIVQTNCSK_BiS2F1 0,0008 1255.5164 
KNG1_HUMAN ITYSIVQTNCSK_TriS2F0 0,0032 1328.5411 
KNG1_HUMAN ITYSIVQTNCSK_TriS2F1 0,0036 1377.2271 
KNG1_HUMAN ITYSIVQTNCSK_TriS3F0 0,0151 1425.5730 
KNG1_HUMAN ITYSIVQTNCSK_TriS3F1 0,0183 1474.2589 
KNG1_HUMAN YNSQNQSNNQFVLYR_BiS2F0 0,0049 1360.5550 
TRFE_HUMAN CGLVPVLAENYNK_BiS0F0 0,0003 1033.7826 
TRFE_HUMAN CGLVPVLAENYNK_BiS1F0 0,0366 1130.8144 
TRFE_HUMAN CGLVPVLAENYNK_BiS1F1 0,0013 1179.5003 
TRFE_HUMAN CGLVPVLAENYNK_BiS2F0 0,1522 1227.8462 
TRFE_HUMAN CGLVPVLAENYNK_BiS2F1 0,0044 1276.5321 
TRFE_HUMAN CGLVPVLAENYNK_TriS1F0 0,0047 1252.5251 
TRFE_HUMAN CGLVPVLAENYNK_TriS2F0 0,0050 1349.5569 
TRFE_HUMAN CGLVPVLAENYNK_TriS3F0 0,0019 1446.5887 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_BiS1F0 0,0077 1476.9386 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_BiS1F1 0,0020 1525.6245 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_BiS2F0 0,1055 1573.9704 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_BiS2F1 0,0088 1622.6563 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_TriS2F0 0,0004 1695.6811 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_TriS3F0 0,0028 1792.7129 
TRFE_HUMAN QQQHLFGSNVTDCSGNFCLFR_TriS3F1 0,0024 1841.3989 
FETUA_HUMAN VCQDCPLLAPLNDTR_BiS1F0 0,0009 1229.1794 
FETUA_HUMAN VCQDCPLLAPLNDTR_BiS2F0 0,0122 1326.2112 
FETUA_HUMAN AALAAFNAQNNGSNFQLEEISR_BiS1F0 0,0005 1426.9482 
FETUA_HUMAN AALAAFNAQNNGSNFQLEEISR_BiS2F0 0,0095 1523.9800 
FETUA_HUMAN AALAAFNAQNNGSNFQLEEISR_BiS2F1 0,0019 1572.6660 
HPT_HUMAN MVSHHNLTTGATLINEQWLLTTAK_BiS1F0 0,0109 1531.6946 
HPT_HUMAN MVSHHNLTTGATLINEQWLLTTAK_BiS2F0 0,0264 1628.7264 
HPT_HUMAN VVLHPNYSQVDIGLIK_BiS1F0 0,0369 1236.9009 
HPT_HUMAN VVLHPNYSQVDIGLIK_BiS2F0 0,2626 1333.9327 
HPT_HUMAN VVLHPNYSQVDIGLIK_BiS2F1 0,0126 1382.6187 
HPT_HUMAN VVLHPNYSQVDIGLIK_TriS1F0 0,0130 1358.6117 
HPT_HUMAN VVLHPNYSQVDIGLIK_TriS2F0 0,0121 1455.6435 
HPT_HUMAN VVLHPNYSQVDIGLIK_TriS3F0 0,0179 1552.6753 
HPT_HUMAN VVLHPNYSQVDIGLIK_TriS3F1 0,0050 1601.3612 
A1AG2_HUMAN LVPVPITNATLDR_BiS1F0 0,0034 1108.1691 
A1AG2_HUMAN LVPVPITNATLDR_BiS2F0 0,0208 1205.2009 
A1AG2_HUMAN LVPVPITNATLDR_TriS2F0 0,0152 1326.9117 
A1AG2_HUMAN LVPVPITNATLDR_TriS2F1 0,0090 1375.5976 
A1AG2_HUMAN LVPVPITNATLDR_TriS3F0 0,0338 1423.9435 
A1AG2_HUMAN LVPVPITNATLDR_TriS3F1 0,0256 1472.6294 
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A1AG2_HUMAN LVPVPITNATLDR_TetraS2F0 0,0006 1448.6224 
A1AG1_HUMAN LVPVPITNATLDQITGK_BiS2F0 0,0085 1328.9361 
A1AG1_HUMAN LVPVPITNATLDQITGK_TriS2F0 0,0060 1450.6469 
A1AG1_HUMAN LVPVPITNATLDQITGK_TriS2F1 0,0027 1499.3328 
A1AG1_HUMAN LVPVPITNATLDQITGK_TriS3F0 0,0168 1547.6787 
A1AG1_HUMAN LVPVPITNATLDQITGK_TriS3F1 0,0120 1596.3647 
A1AG1,2_HUMAN NEEYNK_TriS3F0 0,0009 1219.7873 
A1AG1,2_HUMAN NEEYNK_TriS3F1 0,0008 1268.4732 
A1AG1,2_HUMAN SVQEIQATFFYFTPNK_BiS2F0 0,0032 1375.5803 
A1AG1,2_HUMAN SVQEIQATFFYFTPNK_TriS2F0 0,0005 1497.2910 
A1AG1_HUMAN QDQCIYNTTYLNVQR_BiS2F0 0,0022 1374.2279 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TriS2F0 0,0033 1495.9386 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TriS2F1 0,0016 1544.6246 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TriS3F0 0,0082 1592.9704 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TriS3F1 0,0076 1641.6564 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TetraS1F0 0,0008 1520.6176 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TetraS2F0 0,0072 1617.6494 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TetraS2F1 0,0031 1666.3353 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TetraS3F0 0,0054 1714.6812 
A1AG1_HUMAN QDQCIYNTTYLNVQR_TetraS3F1 0,0031 1763.3671 
 
  
 20 
 
Fig. A: Site-specific glycosylation pattern of alpha-2-HS-glycoprotein and 
serotransferrin. 
Site-specific glycosylation pattern of alpha-2-HS-glycoprotein and serotransferrin in case of 
“A”, “B” and “C” samples for one individual. 
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Fig. B: Correlation between B/A and C/A ratios. 
Correlation between B/A and C/A ratios - changes in the abundance ratio of various 
glycoforms between samples B and A; and that between C and A for one individual. 
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Fig. C: B/A and the corresponding C/A abundance ratios for all glycoforms and 
individuals. 
 
B/A (blue squares) and the corresponding C/A (orange open circles) abundance ratios 
measured for various glycoforms and individuals. Data are arranged in a decreasing series of 
B/A values.  
 
 
 
 
